Tiziana Life Sciences to Host Investor Call
Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company, announced an investor call and webcast scheduled for November 10, 2022, at 10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company, announced an investor call and webcast scheduled for November 10, 2022, at 10 a.m. ET. This session will provide insights into their innovative immunomodulation therapies utilizing novel drug delivery methods. Tiziana's leading candidates include intranasal foralumab and milciclib, both showing promising safety profiles and clinical responses. The company focuses on alternative routes for immunotherapy, aiming to enhance efficacy and safety compared to traditional IV delivery.
Details
News Market Reaction – TLSA
The recorded move for TLSA in the trading session of this news was +1.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and webcast on Thursday, November 10 2022 at 10 a.m. ET.
Dial-in details and webcast information will be provided on the morning of November 10.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.